Kaftrio (Tezacaftor, Elexacaftor, Ivacaftor)

The combination includes two CFTR correctors (elexacaftor and tezacaftor) that assist the misfolded CFTR protein to reach the cell surface, and a CFTR potentiator (ivacaftor) that enhances the opening of the channel once it is present. By increasing both the quantity and activity of CFTR at the epithelial membrane, the drug restores chloride transport and reduces the thick mucus characteristic of cystic fibrosis.

The prescribed dose of Kaftrio is determined by the treating physician based on the patient’s age, weight, and clinical condition. The medication is supplied as a fixed‑dose tablet containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg, and the prescriber decides the number of tablets and dosing schedule appropriate for each individual.

The safety of Kaftrio in pregnancy and lactation has not been fully established, and it is classified as having an unknown pregnancy category. Healthcare providers should weigh the potential benefits against possible risks, and women who are pregnant, planning to become pregnant, or breastfeeding should discuss treatment options and monitoring plans with their specialist.

To request Kaftrio, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will ask for trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any necessary import documentation.

Kaftrio is a triple‑combination CFTR modulator that targets the most common F508del mutation, offering broader coverage than earlier dual‑combination products such as lumacaftor/ivacaftor. Clinical studies have shown greater improvements in lung function and reduced exacerbations, making it a preferred option for eligible patients, while other modulators may be used for different mutation profiles.

Kaftrio tablets should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original blister pack, protect them from moisture, heat and direct sunlight. Do not refrigerate or freeze the product, and ensure the packaging remains sealed until the medication is dispensed.

Kaftrio is taken orally as a whole tablet with a fatty meal to enhance absorption. The tablet should be swallowed whole with water and not split, crushed, or chewed. Patients should follow the dosing schedule prescribed by their physician, which typically involves taking the medication at the same times each day to maintain consistent drug levels.

The most serious risks include liver injury, which may manifest as elevated transaminases or hepatitis, and ocular complications such as cataract formation or retinal pigment changes. Severe allergic reactions, including anaphylaxis, have also been reported. Regular monitoring of liver function tests and periodic eye examinations are recommended to detect these adverse events early.

Kaftrio is